Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evogene Ltd Ord (EVGN)

Evogene Ltd Ord (EVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,043
  • Shares Outstanding, K 5,365
  • Annual Sales, $ 8,510 K
  • Annual Income, $ -16,490 K
  • EBIT $ -14 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.35
  • Price/Sales 0.85
  • Price/Cash Flow N/A
  • Price/Book 0.30
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.25
  • Most Recent Earnings $-0.31 on 11/20/25
  • Next Earnings Date 03/05/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9100 +3.30%
on 02/12/26
1.2400 -24.19%
on 02/04/26
-0.1100 (-10.48%)
since 01/16/26
3-Month
0.9100 +3.30%
on 02/12/26
1.2600 -25.40%
on 11/24/25
-0.2300 (-19.66%)
since 11/18/25
52-Week
0.9100 +3.30%
on 02/12/26
2.4200 -61.16%
on 06/10/25
-0.5400 (-36.49%)
since 02/18/25

Most Recent Stories

More News
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Zoom conference call scheduled for March 5, 2026, 9:00 AM ET

EVGN : 0.9400 (-3.69%)
Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Aiming to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer due to increased expression of cellular pathways

EVGN : 0.9400 (-3.69%)
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

The collaboration is supported by a pan-European EUREKA grant, with participation of the Weizmann Institute of Science

EVGN : 0.9400 (-3.69%)
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

REHOVOT, Israel and BOSTON , Feb. 10, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene" or the "Company"), a pioneering computational chemistry company, specializing in the...

EVGN : 0.9400 (-3.69%)
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

The new collaboration is expected to accelerate, scale and advance small-molecule discovery and optimization for pharmaceutical and agricultural products

EVGN : 0.9400 (-3.69%)
Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board

Appointments Strengthen Scientific Leadership and Support the Acceleration of ChemPass AI™  for Drug and Ag-Chemical Discovery

EVGN : 0.9400 (-3.69%)
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

BMC128 was developed by Biomica, Evogene's subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results

EVGN : 0.9400 (-3.69%)
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design and patient-derived predictive platform...

EVGN : 0.9400 (-3.69%)
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

REHOVOT, Israel , Dec. 30, 2025 /PRNewswire/ --  Evogene Ltd . (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules...

EVGN : 0.9400 (-3.69%)
Evogene: Q3 Earnings Snapshot

Evogene: Q3 Earnings Snapshot

EVGN : 0.9400 (-3.69%)

Business Summary

Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene...

See More

Key Turning Points

3rd Resistance Point 0.9949
2nd Resistance Point 0.9725
1st Resistance Point 0.9562
Last Price 0.9400
1st Support Level 0.9175
2nd Support Level 0.8951
3rd Support Level 0.8788

See More

52-Week High 2.4200
Fibonacci 61.8% 1.8432
Fibonacci 50% 1.6650
Fibonacci 38.2% 1.4868
Last Price 0.9400
52-Week Low 0.9100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar